Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review

被引：19

作者：

Passamonti, Francesco ^{[1
]}

Heidel, Florian H. ^{[2
]}

Parikh, Rohan C. ^{[3
]}

Ajmera, Mayank ^{[3
]}

Tang, Derek ^{[4
]}

Nadal, Jose Alberto ^{[4
]}

Davis, Keith L. ^{[3
]}

Abraham, Pranav ^{[4
]}

机构：

[1] Univ Insubria, Dept Hematol, I-21100 Varese, Italy

[2] Univ Med Greifswald, Internal Med C, D-17475 Greifswald, Germany

[3] RTI Hlth Solut, Hlth Econ, Res Triangle Pk, NC 27709 USA

[4] Bristol Meyers Squibb, Hematol, Lawrenceville, NJ 08648 USA

来源：

FUTURE ONCOLOGY | 2022年 / 18卷 / 18期

关键词：

medical record review; myelofibrosis; real-world data; ruxolitinib; survival analysis; MYELOPROLIFERATIVE NEOPLASMS; AVAILABLE THERAPY; OPEN-LABEL;

D O I：

10.2217/fon-2021-1358

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To assess real-world ruxolitinib treatment patterns and outcomes in patients diagnosed with primary or secondary myelofibrosis. Materials & methods: Patient medical records were reviewed in six countries. Results: Eligible patients (n = 469) had a mean age of 63.5 years, and most were male (66.5%) with primary myelofibrosis (78.5%). Median duration of ruxolitinib treatment was 13.1 months; 40% of patients initiated treatment at the recommended dose. The Kaplan-Meier estimate of median survival from ruxolitinib initiation was 44.4 months (95% CI, 38.8-50.2 months). Approximately one quarter (23%) of patients continued ruxolitinib after progression. Conclusion: These results suggest an unmet need for more effective treatments for patients with myelofibrosis who failed ruxolitinib.

引用

页码：2217 / 2231

页数：15

共 47 条

[21] Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations [J].

Marchetti, M. ;

Barosi, G. ;

Cervantes, F. ;

Birgegard, G. ;

Griesshammer, M. ;

Harrison, C. ;

Hehlmann, R. ;

Kiladjian, J-J ;

Kroeger, N. ;

McMullin, M. F. ;

Passamonti, F. ;

Vannucchi, A. ;

Barbui, T. .

LEUKEMIA, 2017, 31 (04) :882-888

[22] Two Phase 1b Studies Evaluating the Safety and Tolerability of BET Inhibitors, ABBV-744 and Mivebresib, as Monotherapies and in Combination with Ruxolitinib or Navitoclax in Patients with Myelofibrosis [J].

Mascarenhas, John ;

Saab, Rabih ;

Brackman, Deanna ;

Modi, Dimple A. ;

Abraham, Linu ;

Ward, James E. ;

Verstovsek, Srdan .

BLOOD, 2020, 136

[23] Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies [J].

Mesa, Ruben A. ;

Talpaz, Moshe ;

Kiladjian, Jean-Jacques ;

Harrison, Claire N. ;

Verstovsek, Srdan ;

Buckley, Sarah A. ;

Roman-Torres, Karisse ;

Mascarenhas, John .

BLOOD, 2019, 134

[24] Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing [J].

Mesa, Ruben A. ;

Cortes, Jorge .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6

[25] Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial [J].

Mesa, Ruben A. ;

Gotlib, Jason ;

Gupta, Vikas ;

Catalano, John V. ;

Deininger, Michael W. ;

Shields, Alan L. ;

Miller, Carole B. ;

Silver, Richard T. ;

Talpaz, Moshe ;

Winton, Elliott F. ;

Harvey, Jimmie H. ;

Hare, Thomas ;

Erickson-Viitanen, Susan ;

Sun, William ;

Sandor, Victor ;

Levy, Richard S. ;

Kantarjian, Hagop M. ;

Verstovsek, Srdan .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (10) :1285-1292

[26] Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia [J].

Mora, Barbara ;

Giorgino, Toni ;

Guglielmelli, Paola ;

Rumi, Elisa ;

Maffioli, Margherita ;

Rambaldi, Alessandro ;

Caramella, Marianna ;

Komrokji, Rami ;

Gotlib, Jason ;

Kiladjian, Jean Jacques ;

Cervantes, Francisco ;

Devos, Timothy ;

Palandri, Francesca ;

De Stefano, Valerio ;

Ruggeri, Marco ;

Silver, Richard T. ;

Benevolo, Giulia ;

Albano, Francesco ;

Cavalloni, Chiara ;

Barraco, Daniela ;

Pietra, Daniela ;

Barbui, Tiziano ;

Rotunno, Giada ;

Vannucchi, Alessandro Maria ;

Passamonti, Francesco .

LEUKEMIA RESEARCH, 2018, 69 :100-102

[27]

National Comprehensive Cancer Network, 2021, MYEL NEOPL

[28]

O'Sullivan J, 2018, CLIN ADV HEMATOL ONC, V16, P121

[29] How I treat myelofibrosis after failure of JAK inhibitors [J].

Pardanani, Animesh ;

Tefferi, Ayalew .

BLOOD, 2018, 132 (05) :492-500

[30] New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms [J].

Passamonti, Francesco ;

Mora, Barbara ;

Maffioli, Margherita .

CURRENT OPINION IN HEMATOLOGY, 2016, 23 (02) :137-143

← 1 2 3 4 5 →